抑制CDC25C可以减弱IL-17A驱动的角质细胞过度增殖和牛皮的进展
Xuejiao Liang1, Ningxin Wang1, Quanyao Yang2
1State Key Laboratory of Pharmaceutical Biotechnology, Department of Clinical Nutrition, Nanjing Drum Tower Hospital, School of Life Sciences, Nanjing University, Nanjing, China.
Biochemical and biophysical research communications
|January 26, 2026
概括
牛皮涉及过度的皮肤细胞生长由IL-17驱动. 针对非正规IL-17通路中的关键蛋白质CDC25C,有效地减少了模型中的皮肤细胞增殖和增生,提供了一种新的治疗策略.
科学领域:
- 皮肤病学 皮肤病学
- 分子生物学分子生物学
- 免疫学 免疫学 免疫学
背景情况:
- 牛皮是一种IL-17驱动的慢性炎症性皮肤病.
- 目前的抗IL-17疗法显示效果不完全,需要新的点.
- 以前,CDC25C被确定为非正规IL-17A通路中的关键效应因子.
研究的目的:
- 探索针对牛皮的CDC25C的治疗潜力.
- 调查CDC25C在IL-17驱动的角质细胞过度增殖中的作用.
主要方法:
- 从牛皮患者的单细胞RNA-seq数据集的分析.
- 使用IL-17A刺激和CDC25C抑制的体外研究 (NSC95397).
- 在体内研究使用IMQ诱导的类似牛皮的小鼠模型.
主要成果:
- CDC25C在牛皮皮肤上升调节,并富含增殖性角质细胞.
- 抑制CDC25C抑制了角质细胞的过度增殖和迁移,而不会影响关键的炎症性细胞因子.
- 在小鼠模型中,抑制CDC25C缓解了表皮增生症和腹壮大.
- 预防性使用NSC95397比治疗治疗更有保护性.
结论:
- CDC25C是IL-17驱动的角质细胞过度增殖的关键媒介.
- 抑制CDC25C是一种有前途的牛皮治疗策略.
- CDC25C可能在牛皮的早期发病中起作用.
相关概念视频
Transcription Attenuation in Prokaryotes
18.4K
Transcriptional attenuation occurs when RNA transcription is prematurely terminated due to the formation of a terminator mRNA hairpin structure. Bacteria use these hairpins to regulate the transcription process and control the synthesis of several amino acids including histidine, lysine, threonine, and phenylalanine. Transcription attenuation takes place in the non-coding regions of mRNA.
There are several different mechanisms used to attenuate transcription. In ribosome mediated...
There are several different mechanisms used to attenuate transcription. In ribosome mediated...
18.4K
Feedback Inhibition
57.1K
Biochemical reactions are occurring constantly in cells, converting starting substances to different products, usually with the help of enzymes that speed the reactions. Without enzymes, it would take far too long for most reactions to occur to be useful to the cell!
57.1K
Tumor Progression
7.4K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.4K
Enzyme Inhibition
91.9K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
91.9K
mTOR Signaling and Cancer Progression
4.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.7K
Inhibition of Cdk Activity
6.0K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.0K


